Revolutionizing Molecular Diagnostics: Italy

Italy displays moderate awareness of Next-Generation Sequencing (NGS), bridging research and clinical applications. Labs prioritize ISO standards for NGS services, but there’s a need for specialized training in interpreting data and managing workflows.

Molecular Tumor Boards meet regularly, supporting cancer management. NGS is reimbursed, except for Liquid Biopsy, aside from lung cancer, where special funding exists. Italy lacks external quality assessments for NGS, impacting testing quality.

Healthcare faces workforce shortages, particularly in cancer care. Cross-border data sharing occurs, but stronger security guidelines and dedicated oversight are needed for data protection and integration.

For more, refer to the factsheet below.

If you like it, share it